Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Antineoplaston A2
- Development stage
- Unknown
- Lead developer
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Antineoplaston A2 is a peptide-derived small molecule therapeutic developed by the Burzynski Clinic for the treatment of cancer. It belongs to a group of naturally occurring peptides and amino acid derivatives, originally identified in human blood and urine, which are claimed to act as "biochemical correctors" that normalize the growth of neoplastic cells. Antineoplaston A2 is administered via intravenous injection and is currently in Phase 1 clinical development. Despite decades of study by the developer, the specific molecular targets and mechanism of action remain poorly defined in independent scientific literature.
- Other names
- A2A-2A 2
Beyond the preview
Go deeper on Antineoplaston A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Antineoplaston A2.